1[1]U. S. Food and Drug Administration, Center for Biologics Evaluation and Research: Licensed/Approved HIV, HTLV and Hepatitis Tests.Information last updated, 1999, 9, 29
2[2]Bush MP, Lee LL, Satten GA et al: Time course of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implication for screening of blood and tissue donors. Transfusion, 1995, 35(2): 91～97
3[3]Gurtler LG, Eberle J, Lorbeer B et al: Sensitivity and specificity of commercial ELISA kits for screening anti - LAV/HTLV Ⅲ. J Virol Methods, 1987, 15:11～23
4[4]Taylor RN, Przybyszewski VA: Summary of the Centers for Disease Control human immunodeficiency virus (HIV) performance evaluation surveys for 1985 and 1986. Am J Clin Pathol, 1988, 89(1): 1～13
5[5]Petricciani JC, Epstein JS: The effect of the AIDS epidemic on the safety of the nation's blood supply. Public Health Rep, 1988, 103(3): 236～241
6[6]Clavel F, Guyader M, Guard D et al: Molecular cloning and polymorphism of the human immunodeficiency virus type 2. Nature, 1986,324(6098): 691～695
7[7]George JR, Rafield MA, Phillips S, et al: Efficacies of US Food and Drug Administration - licensed HIV - 1 screening enzyme immunoassay for detecting antibodies to HIV- 2. AIDS, 1990, 4(4): 321～326
8[8]Barb F, Klein M, Badonnel Y: Early detection of antibodies to human immunodeficiency virus 1 by a third generation enzyme immunoassay.A comparative study with the results of second generation immunoassay and western blot. Ann Biol Clin (Paris), 1994, 52(5): 341～345
9[9]L. G. Guriler, L. Zekeng, F. Simon et al: Reactivity of five antiHIV- 1 subtype O specimens with six different anti- HIV screening ELISAs and three immunoblots. J Virol Methods, 1995, 51(2～3):177～183
